APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04214860 |
|
Recruitment Status :
Completed
First Posted : January 2, 2020
Last Update Posted : January 19, 2022
|
Sponsor:
Aprea Therapeutics
Information provided by (Responsible Party):
Aprea Therapeutics
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | January 14, 2022 |
| Actual Study Completion Date : | January 14, 2022 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
February 27, 2024 |